Literature DB >> 23409771

Degradation of target coverage due to inter-fraction motion during intensity-modulated proton therapy of prostate and elective targets.

Sara Thörnqvist1, Ludvig P Muren, Lise Bentzen, Liv B Hysing, Morten Høyer, Cai Grau, Jørgen B B Petersen.   

Abstract

UNLABELLED: Internal target and organ motion during treatment is a challenge in radiotherapy (RT) of the prostate and the involved elective targets, with residual motion being present also following image-guidance strategies. The aim of this study was to investigate organ motion-induced dose degradations for the prostate, seminal vesicle and the pelvic lymph node when treating these targets with proton therapy, using different image-guidance and delivery strategies.
MATERIAL AND METHODS: Four patients were selected from a larger series as they displayed large inter-fractional variation in bladder and rectum volume. Intensity-modulated proton therapy plans were generated using both simultaneous integrated and sequential boost delivery. For each technique, three isotropic margin expansions (in the range of 4-10 mm) were evaluated for the clinical target volume of prostate (CTV-p), seminal vesicles (CTV-sv) and lymph nodes (CTV-ln). Simulation of the dose degradations for all treatment plans were based on dose re-calculations for the 8-9 repeat CTs available for each patient, after applying rigid registrations to reproduce set-up based on either intra-prostatic fiducials or bony anatomy.
RESULTS: The simulated dose received by 99% of the target volume (D(99)) and generalized equivalent dose (gEUD) showed substantial inter-patient variations. For 40% of the investigated scenarios, the patient average simulated D(99) for all targets were within 2 GyE from the planned dose. The largest difference between simulated and planned dose was seen for the CTV-sv when using SIB delivery, with an average relative reduction in D(99) of 13% and 15% for the largest margin expansion, when positioned using fiducials and bony anatomy, respectively.
CONCLUSIONS: The most severe dose degradations were found for CTV-sv, but they were also evident for CTV-ln. The degradations could not be completely resolved, neither by using the largest margin expansion nor with the choice of set-up. With fiducial set-up CTV-p was robust against the inter-fraction changes.

Entities:  

Mesh:

Year:  2013        PMID: 23409771     DOI: 10.3109/0284186X.2012.752860

Source DB:  PubMed          Journal:  Acta Oncol        ISSN: 0284-186X            Impact factor:   4.089


  10 in total

1.  Bone marrow sparing in intensity modulated proton therapy for cervical cancer: Efficacy and robustness under range and setup uncertainties.

Authors:  Eric Dinges; Nicole Felderman; Sarah McGuire; Brandie Gross; Sudershan Bhatia; Sarah Mott; John Buatti; Dongxu Wang
Journal:  Radiother Oncol       Date:  2015-05-13       Impact factor: 6.280

2.  Multiple Computed Tomography Robust Optimization to Account for Random Anatomic Density Variations During Intensity Modulated Proton Therapy.

Authors:  Mingyao Zhu; Adeel Kaiser; Mark V Mishra; Young Kwok; Jill Remick; Cristina DeCesaris; Katja M Langen
Journal:  Adv Radiat Oncol       Date:  2019-12-26

3.  Short-course PET based simultaneous integrated boost for locally advanced cervical cancer.

Authors:  Marius Røthe Arnesen; Bernt Louni Rekstad; Caroline Stokke; Kjersti Bruheim; Ayca Muftuler Løndalen; Taran Paulsen Hellebust; Eirik Malinen
Journal:  Radiat Oncol       Date:  2016-03-12       Impact factor: 3.481

4.  A modeling study of functional magnetic resonance imaging to individualize target definition of seminal vesicles for external beam radiotherapy.

Authors:  Sidsel Damkjær; Jakob B Thomsen; Svetlana I Petersen; Jens Peter Bangsgaard; Peter M Petersen; Ivan R Vogelius; Marianne C Aznar
Journal:  Acta Oncol       Date:  2017-03-15       Impact factor: 4.089

5.  On-line dose-guidance to account for inter-fractional motion during proton therapy.

Authors:  Kia Busch; Ludvig P Muren; Sara Thörnqvist; Andreas G Andersen; Jesper Pedersen; Lei Dong; Jørgen B B Petersen
Journal:  Phys Imaging Radiat Oncol       Date:  2018-12-19

6.  Evaluation of an a priori scatter correction algorithm for cone-beam computed tomography based range and dose calculations in proton therapy.

Authors:  Andreas Gravgaard Andersen; Yang-Kyun Park; Ulrik Vindelev Elstrøm; Jørgen Breede Baltzer Petersen; Gregory C Sharp; Brian Winey; Lei Dong; Ludvig Paul Muren
Journal:  Phys Imaging Radiat Oncol       Date:  2020-10-27

7.  A biological modelling based comparison of radiotherapy plan robustness using photons vs protons for focal prostate boosting.

Authors:  Jesper Pedersen; Oscar Casares-Magaz; Jørgen B B Petersen; Jarle Rørvik; Lise Bentzen; Andreas G Andersen; Ludvig P Muren
Journal:  Phys Imaging Radiat Oncol       Date:  2018-07-18

8.  Prostate-Centric Versus Bony-Centric Registration in the Definitive Treatment of Node-Positive Prostate Cancer with Simultaneous Integrated Boost: A Dosimetric Comparison.

Authors:  Trudy C Wu; Michael Xiang; Nicholas G Nickols; Stephen Tenn; Nzhde Agazaryan; John V Hegde; Michael L Steinberg; Minsong Cao; Amar U Kishan
Journal:  Adv Radiat Oncol       Date:  2022-03-16

Review 9.  Proton therapy- the modality of choice for future radiation therapy management of Prostate Cancer?

Authors:  Sophie Mangan; Michelle Leech
Journal:  Tech Innov Patient Support Radiat Oncol       Date:  2019-10-11

10.  Dosimetric advantages of daily adaptive strategy in IMPT for high-risk prostate cancer.

Authors:  Hiroshi Tamura; Keiji Kobashi; Kentaro Nishioka; Takaaki Yoshimura; Takayuki Hashimoto; Shinichi Shimizu; Yoichi M Ito; Yoshikazu Maeda; Makoto Sasaki; Kazutaka Yamamoto; Hiroyasu Tamamura; Hidefumi Aoyama; Hiroki Shirato
Journal:  J Appl Clin Med Phys       Date:  2022-01-19       Impact factor: 2.102

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.